Trial Profile
"The effect of Six months Adalimumab Treatment on Sick Leaves and retirement in Patients with rheumatoid Arthritis who are at risk of losing their ability to work".
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Oct 2022
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Disease-modifying antirheumatics
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms REWARD
- 12 Oct 2022 Status changed from recruiting to completed.
- 28 Jul 2011 Additional lead trial centers ans investigators identified as reported by ClinicalTrials.gov.
- 28 Jul 2011 Planned end date changed from 13 Aug 2010 to 1 Mar 2011 as reported by ClinicalTrials.gov..